Carbylan Therapeutics, which is developing a novel, injectable treatment for osteoarthritis pain in the knee, postponed its planned $75 million IPO. The Palo Alto, CA-based company, which was founded in 2004, would have had a $211 million market cap had it priced at its $13 midpoint. Leerink Partners was set to be the sole bookrunner on the deal.
